By Connor Hart
AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area.
The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business.
The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said.
"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government," Chief Executive Pascal Soriot said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 23, 2025 14:54 ET (19:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.